Matthew Szot's Securities Transactions in Cadrenal Therapeutics Inc.

Matthew Szot, an officer at Cadrenal Therapeutics Inc., has filed a Form 144 notice detailing his securities transactions. The filing indicates that Szot plans to sell 1,800 common shares acquired as Founders Shares on May 17, 2022. The sale is scheduled for October 24, 2025, with an aggregate market value of $24,786.00. Additionally, the filing discloses Szot's recent securities sales over the past three months, totaling 18,000 shares with gross proceeds exceeding $300,000. These transactions were executed under a 10b5-1 trading plan, which allows insiders to sell shares at predetermined times to avoid accusations of insider trading. The filing highlights Szot's ongoing divestment of his holdings in the company.